Abstract Background Porcine pleuropneumonia, caused by Actinobacillus pleuropneumoniae, is a bacterial respiratory disease of swine. Acute outbreaks of the disease are often accompanied by high mortality and economic losses. As severe cases of the disease frequently require parenteral antibiotic treatment of the animals, the efficacy of a single, high dose of marbofloxacin was compared to a three-time application of a dose of enrofloxacin under experimental conditions. Methods A blinded, controlled, randomized and blocked dose confirmation study was conducted to test the efficacy and safety of a single dose of 8 mg/kg marbofloxacin (160 mg/ml, Forcyl® Swine, Vetoquinol SA, France) to treat acute porcine pleuropneumonia after experimental ae...
Piglets with large-scale respiratory pathologies caused by a bacterial flora susceptible to phenicol...
Objective: To evaluate the efficacy of two new-generation porcine pleuropneumonia vaccines when cha...
OBJECTIVES: Latest trials failed to confirm merits of nebulized amikacin for critically ill patients...
Abstract Background Acute outbreaks of Actinobacillus pleuropneumoniae (APP) require rapid, effectiv...
The efficacy of an Actinobacillus pleuropneumoniae subunit vaccine based on ApxIA, ApxIIA, ApxIIIA a...
The pharmacokinetics of marbofloxacin in pigs after intravenous (i.v.), intramuscular (i.m.), and pe...
La marbofloxacina (MB) és una fluoroquinolona de tercera generació àmpliament usada en diferents esp...
Porcine pleuropneumonia is of serious concern regarding lung health in pig production. Besides optim...
This study evaluated the theoretical clinical outcome of three marbofloxacin posology regimens in tw...
Porcine respiratory disease complex (PRDC) is a major economic problem for swine producers world-wid...
Abstract Background Bacterial pneumonia in pigs occurs widely and requires antimicrobial therapy. It...
Objective: To evaluate lung lesions at slaughter after three-dose vaccination with a subunit Actinob...
Objective: To evaluate lung lesions at slaughter after three-dose vaccination with a subunit Actinob...
The efficacy of two inactivated vaccines containing the Apx toxins of Actinobacillus pleuropneumonia...
Objective: To determine the efficacy of injectable meloxicam as adjunctive therapy to antimicrobial ...
Piglets with large-scale respiratory pathologies caused by a bacterial flora susceptible to phenicol...
Objective: To evaluate the efficacy of two new-generation porcine pleuropneumonia vaccines when cha...
OBJECTIVES: Latest trials failed to confirm merits of nebulized amikacin for critically ill patients...
Abstract Background Acute outbreaks of Actinobacillus pleuropneumoniae (APP) require rapid, effectiv...
The efficacy of an Actinobacillus pleuropneumoniae subunit vaccine based on ApxIA, ApxIIA, ApxIIIA a...
The pharmacokinetics of marbofloxacin in pigs after intravenous (i.v.), intramuscular (i.m.), and pe...
La marbofloxacina (MB) és una fluoroquinolona de tercera generació àmpliament usada en diferents esp...
Porcine pleuropneumonia is of serious concern regarding lung health in pig production. Besides optim...
This study evaluated the theoretical clinical outcome of three marbofloxacin posology regimens in tw...
Porcine respiratory disease complex (PRDC) is a major economic problem for swine producers world-wid...
Abstract Background Bacterial pneumonia in pigs occurs widely and requires antimicrobial therapy. It...
Objective: To evaluate lung lesions at slaughter after three-dose vaccination with a subunit Actinob...
Objective: To evaluate lung lesions at slaughter after three-dose vaccination with a subunit Actinob...
The efficacy of two inactivated vaccines containing the Apx toxins of Actinobacillus pleuropneumonia...
Objective: To determine the efficacy of injectable meloxicam as adjunctive therapy to antimicrobial ...
Piglets with large-scale respiratory pathologies caused by a bacterial flora susceptible to phenicol...
Objective: To evaluate the efficacy of two new-generation porcine pleuropneumonia vaccines when cha...
OBJECTIVES: Latest trials failed to confirm merits of nebulized amikacin for critically ill patients...